Literature DB >> 19106805

The antioxidant Cerebralcare Granule attenuates cerebral microcirculatory disturbance during ischemia-reperfusion injury.

Xiang-Shun Xu1, Zhi-Zhong Ma, Fang Wang, Bai-He Hu, Chuan-She Wang, Yu-Ying Liu, Xin-Rong Zhao, Li-Hua An, Xin Chang, Fu-Long Liao, Jing-Yu Fan, Hideyuki Niimi, Jing-Yan Han.   

Abstract

Cerebralcare Granule (CG) is a compound Chinese medicine used for treatment of headache and dizziness associated with cerebrovascular diseases. To clarify the mechanism underlying the clinical outcome of CG, this study investigated the effects of CG on the structure and function of cerebral microvasculature during I/R injury. A total of 138 Mongolian gerbils were included and divided into four groups, each composed of 36 or 30 animals, for evaluating various parameters of concern. A skull window was prepared for microcirculatory observation in animals, which were subjected to I/R with or without pretreatment with CG (0.4 or 0.8 g/kg). The velocity of red blood cells in the venules was observed by a high-speed video camera system, along with intravital confocal microscopic measurements of microvascular diameters, adherent leukocytes, and albumin leakage in the brain cortex. Changes in the fluorescence intensity of dihydrorhodamine 123 in cerebral microvessels and malondialdehyde level in the cortex were measured. The ultrastructure of the microvessels in the cerebral cortex was analyzed using both transmission and scanning electron microscopy. In addition, cerebral blood flow was monitored using the laser Doppler imaging technique. Pretreatment with CG (0.4 or 0.8 g/kg) significantly alleviated I/R injury-induced disorders in cerebral microvasculature, as evidenced by the data observed at 60 min of reperfusion wherein the values in CG (0.4 g/kg) pretreatment group, CG (0.8 g/kg) pretreatment group, and I/R group were 2.43 +/- 0.24, 2.28 +/- 0.18, and 6.00 +/- 0.35 for leukocyte adhesion, 2.51 +/- 0.40, 2.33 +/- 0.29, and 4.77 +/- 0.24 for albumin leakage, 7.06 +/- 0.81, 5.93 +/- 0.42, and 28.38 +/- 2.70 for dihydrorhodamine 123 fluorescence intensity in cerebral microvessels, 16.35 +/- 0.52, 14.34 +/- 0.68, and 21.46 +/- 0.71 for malondialdehyde level in the cortex, and 0.43 +/- 0.07, 0.46 +/- 0.02, and 0.17 +/- 0.08 for cerebral blood flow, respectively. I/R injury-elicited ultrastructural alterations in microvessels in cerebral cortex were also mitigated impressively by CG administration, manifested as attenuation of the reduced number of opening capillaries and the altered fine structures in endothelium, which were characterized by rough inner surface, increased intracellular vesicles, hypertrophy of digitations of intercellular contact, and swollen perivascular astroglial processes. Cerebralcare Granule is able to attenuate I/R injury-induced functional and structural changes in microvessels in the cerebral cortex of gerbils, an ability that is most likely correlated with its antioxidant potential.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19106805     DOI: 10.1097/SHK.0b013e3181996d61

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  17 in total

1.  The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine.

Authors:  Youyou Tu
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

2.  Cerebralcare Granule(®), a Chinese Herb Compound Preparation, Attenuates D-Galactose Induced Memory Impairment in Mice.

Authors:  Zhuo Qu; Honggai Yang; Jingze Zhang; Liqin Huo; Hong Chen; Yuming Li; Changxiao Liu; Wenyuan Gao
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

3.  Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies.

Authors:  Kimihiro Nagatani; Hiroshi Nawashiro; Satoru Takeuchi; Satoshi Tomura; Naoki Otani; Hideo Osada; Kojiro Wada; Hiroshi Katoh; Nobusuke Tsuzuki; Kentaro Mori
Journal:  Med Gas Res       Date:  2013-06-25

4.  Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.

Authors:  Xiao-Wei Mao; Chun-Shui Pan; Ping Huang; Yu-Ying Liu; Chuan-She Wang; Li Yan; Bai-He Hu; Xin Chang; Ke He; Huan-Na Mu; Quan Li; Kai Sun; Jing-Yu Fan; Jing-Yan Han
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

5.  Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson's disease.

Authors:  Weidong Pan; Shin Kwak; Guoyan Li; Yiyun Chen; Dingfang Cai
Journal:  Chin Med       Date:  2013-07-27       Impact factor: 5.455

6.  Effect of salvianolic acid B on TNF-α induced cerebral microcirculatory changes in a micro-invasive mouse model.

Authors:  Bo Chen; Kai Sun; Yu-Ying Liu; Xiang-Shun Xu; Chuan-She Wang; Ke-Seng Zhao; Qiao-Bing Huang; Jing-Yan Han
Journal:  Chin J Traumatol       Date:  2016-04-01

7.  Radix Ilicis Pubescentis total flavonoids ameliorates neuronal damage and reduces lesion extent in a mouse model of transient ischemic attack.

Authors:  Ming-San Miao; Lin Guo; Rui-Qi Li; Xiao-Lei Zhang
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135

8.  Neuroprotective effect of Cerebralcare Granule after cerebral ischemia/reperfusion injury.

Authors:  Xiao-Xiao Zhang; Fen-Fen He; Gui-Lin Yan; Ha-Ni Li; Dan Li; Yan-Ling Ma; Fang Wang; Nan Xu; Fei Cao
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

9.  Cerebralcare Granule® attenuates cognitive impairment in rats continuously overexpressing microRNA-30e.

Authors:  Yong Xu; Zhifen Liu; Xi Song; Kerang Zhang; Xingrong Li; Jianhong Li; Xu Yan; Yuan Li; Zhongchen Xie; Hui Zhang
Journal:  Mol Med Rep       Date:  2015-10-22       Impact factor: 2.952

Review 10.  Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage.

Authors:  Kai Sun; Jingyu Fan; Jingyan Han
Journal:  Acta Pharm Sin B       Date:  2015-01-24       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.